Enhabit Q4 revenue rises

Enhabit

04/03/2026 21:21

Overview

Home health and hospice provider's Q4 revenue rose 4.7% yr/yr

Adjusted EBITDA for Q4 beat analyst expectations

Outlook

Enhabit suspends financial guidance due to pending merger with Kinderhook

Result Drivers

NON-MEDICARE GROWTH - Enhabit reported a 16.0% increase in non-Medicare admissions, contributing to a 3.2% rise in home health net service revenue

HOSPICE CENSUS INCREASE - Hospice average daily census grew 9.9% year over year, boosting net service revenue by 10.0%

COST REDUCTION - Home health cost per patient day decreased 3.5% year over year, aiding margin improvement

Company press release: ID:nBwbgNRBha

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q4 Adjusted EPS
Meet
$0.14
$0.14 (6 Analysts)
Q4 EPS
-$0.76
Q4 Gross Margin
48.7%
Q4 Adjusted EBITDA Margin
10.4%


Analyst Coverage

The current average analyst rating on the shares is "hold" and the breakdown of recommendations is 1 "strong buy" or "buy", 5 "hold" and no "sell" or "strong sell"

The average consensus recommendation for the healthcare facilities & services peer group is "buy."

Wall Street's median 12-month price target for Enhabit Inc is $13.80, about 1.5% above its March 3 closing price of $13.60

The stock recently traded at 22 times the next 12-month earnings vs. a P/E of 16 three months ago

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)